IMpower010: Primary Results of a Phase 3 Global Study of Atezolizumab vs Best Supportive Care After Adjuvant Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)
IMpower010 is a randomized, open-label, phase III study of adjuvant atezolizumab compared with best supportive care in patients with completely resected stage IB-IIIA NSCLC who received adjuvant cisplatin-based chemotherapy. Here, we present the primary efficacy endpoint of disease-free survival (DFS), which was tested hierarchically in the PD-L1 tumor cell ≥1% (SP263) subgroup of the stage II-IIIA population, then the all-randomized stage II-IIIA population and then the intent-to-treat population (stage IB-IIIA), as well as key secondary endpoints and safety.